News about "Merck"

Merck Reports Positive Phase 2b Tulisokibart Results in Hidradenitis Suppurativa

Merck reported Phase 2b results for investigational tulisokibart in patients with moderate to severe hidradenitis suppurativa.

Merck | 01/10/2026 | By News Bureau

FDA Updates Winrevair Label With Phase 3 HYPERION Data

Merck’s Winrevair label has been updated by the US FDA to include data from the Phase 3 HYPERION trial in recently diagnosed adults with pulmonary arterial hypertension.

Merck | 23/09/2026 | By News Bureau

Japan Approves Merck's Keytruda Qlex for Subcutaneous Use

Merck’s Keytruda Qlex receives MHLW approval in Japan for subcutaneous use across all locally approved Keytruda indications.

Merck | 22/09/2026 | By News Bureau

Merck Gets Positive EU Opinion for Keytruda-Padcev in MIBC

Merck’s Keytruda plus Padcev receives a positive CHMP opinion for perioperative treatment of adults with resectable muscle-invasive bladder cancer, with the EC set to review the recommendation.

Merck | 19/09/2026 | By News Bureau

Merck Expands Jigani Facility to Boost Life Science Manufacturing

Merck has invested approximately Euro 13 million to expand its Jigani, Bengaluru facility with new biological buffer manufacturing capabilities.

Merck | 18/09/2026 | By News Bureau |  157

Merck Delivers Robust Q2 2026 Performance

Merck reported strong Q2 2026 results with 4.1 percent organic sales growth, higher EBITDA, upgraded full-year guidance and planned Bio-Techne acquisition.

Merck | 06/08/2026 | By News Bureau |  121

Merck Wins US FDA Breakthrough Therapy Designation Status for Enpatoran in Lupus

Merck has received US Food and Drug Administration (FDA) Breakthrough Therapy Designation (BTD) for enpatoran in lupus patients with active skin manifestations, advancing a potential first approved treatment for cutaneous lupus.

Merck | 09/07/2026 | By News Bureau

US FDA Approves KEYTRUDA and KEYTRUDA QLEX, Each with Trodelvy

The US Food and Drug Administration (FDA) has approved KEYTRUDA and KEYTRUDA QLEX in combination with Trodelvy as first-line treatment for adults with PD-L1-positive (CPS ≥10) advanced Triple-Negative Breast Cancer (TNBC).

Merck | 26/06/2026 | By News Bureau |  215

Merck Partners with Versant Ventures to Launch Saturnus Bio

Merck has partnered with Versant Ventures to establish Saturnus Bio, advancing precision medicine through gene modulation technologies for rare genetic cardiomyopathies.

Merck | 25/06/2026 | By News Bureau |  118

Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 3 ATLAS-UC Induction

Merck’s tulisokibart achieved both primary and key secondary endpoints in the phase 3 ATLAS-UC induction study, demonstrating significant efficacy in patients with moderately to severely active Ulcerative Colitis (UC).

Merck | 23/06/2026 | By News Bureau |  455